Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

R&D productivity: on the comeback trail

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1: Number and aggregate peak sales value of new therapeutic drugs by year of FDA approval.
Figure 2: R&D productivity data.

References

  1. 1

    Tollman, P. et al. Identifying R&D outliers. Nature Rev. Drug Discov. 10, 653–654 (2011).

    CAS  Article  Google Scholar 

  2. 2

    Ringel, M. et al. Does size matter in R&D productivity? If not, what does? Nature Rev. Drug Discov. 12, 901–902 (2013).

    CAS  Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Ulrik Schulze.

Ethics declarations

Competing interests

The authors of this article are employees of The Boston Consulting Group (BCG), a management consultancy that works with the world's leading biopharmaceutical companies on R&D productivity issues. The research for this specific article was funded by BCG's Health Care practice.

Supplementary information

Supplementary information S1 (box)

Data and analysis (PDF 70 kb)

Supplementary information S2 (figure)

Aggregate industry spending on research and development. (PDF 202 kb)

PowerPoint slides

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Schulze, U., Baedeker, M., Chen, Y. et al. R&D productivity: on the comeback trail. Nat Rev Drug Discov 13, 331–332 (2014). https://doi.org/10.1038/nrd4320

Download citation

Further reading

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing